Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.1.4 - fructokinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acromegaly
Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Plasma LH, FSH and TSH responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Acute Kidney Injury
Acute kidney injury: Benefits of blocking fructokinase.
Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice.
The sweetest thing: blocking fructose metabolism to prevent acute kidney injury?
[Pancreas transplant pathology: clinicopathologic and experimental findings]
Addison Disease
Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.
Effects of ovine corticotropin-releasing hormone and FK 33-824 (met-enkephalin analogue) on the secretions of proopiomelanocortin-derived N-terminal peptide, beta-lipotropin, beta-endorphin and adrenocorticotropin in patients with Addison's disease.
Adenocarcinoma
Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973).
Adenoma
FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.
Alopecia
Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia.
Alopecia Areata
Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata.
Anemia
Anaemia associated with FK 506 immunosuppression.
Anemia, Hemolytic
Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy.
Aphasia
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Arteriosclerosis
FK 506 inhibits the development of transplant arteriosclerosis.
Arthritis
Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development.
Arthritis, Experimental
Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report.
Aspergillosis
The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression.
[Immunosuppression: a case of mucoviscidosis]
Asthma
Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients.
[Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]
Atherosclerosis
Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis.
Functional analysis of the fractalkine gene promoter in human aortic smooth muscle cells exposed to proinflammatory conditions.
Autoimmune Diseases
FK 506 and autoimmune disease: perspective and prospects.
FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.
Functional and structural characteristics of experimental FK 506 nephrotoxicity.
[Clinical experience with FK 506]
Bacterial Infections
A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.
Effect of RS61443 in combination with leflunomide or FK506 on rat heart allograft survival.
Persistence of Innate Immune Pathways in Late Stage Human Bacterial and Fungal Keratitis: Results from a Comparative Transcriptome Analysis.
Blepharitis
[FK 506 ointment 0.1 % - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients]
Blindness
Evaluation of Liposomal and Conventional Amphotericin B in Experimental Fungal Keratitis Rabbit Model.
Bradycardia
Addition of Low-Dose Ketamine to Propofol-Fentanyl Sedation for Gynecologic Diagnostic Laparoscopy: Randomized Controlled Trial.
Cardiorespiratory effects of D-Ala-2-Me-Phe-4-Met-(0)-ol enkephalin in the third ventricle, and in anterior hypothalamic and paraventricular areas of the rat brain.
Cardiorespiratory responses to D-Ala-2-Me-Phe-4-Met-(O)-ol-enkephalin after administration into the fourth cerebral ventricle of the rat: interaction with cholinergic mechanisms.
Perfusion of the fourth cerebral ventricle with the synthetic opioid peptide, FK 33-824, induces dose-related bradycardia and naloxone-reversible respiratory depression in the awake dog.
Brain Edema
A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.
Brain Ischemia
[The effect of FK 506, an immunosuppressant, on cerebral infarction volume in focal cerebral ischemia in rats]
Breast Neoplasms
[Phase I study of FK 435]
Bronchiolitis
FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.
Bronchiolitis Obliterans
FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation.
Candidiasis
FK 506/fluconazole interaction enhances FK 506 nephrotoxicity.
[The future of antifungal agents. Non azole antifungal agents]
Carcinogenesis
Effect of bile acids and dietary fat on large bowel carcinogenesis in animal models.
Effect of FK 506 on experimental liver carcinogenesis.
Carcinoma
Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1.
Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Immunosuppressive drugs and their effect on experimental tumor growth.
[Experimental gene therapy mediated by fractalkine (FK) for murine liver cancer]
Carcinoma, Hepatocellular
A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation.
Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
[Activity of enzymes of glycolysis and gluconeogenesis in primary hepatomas induced by diethylnitrosamine]
[Experimental gene therapy mediated by fractalkine (FK) for murine liver cancer]
Catatonia
Strain dependent effects of the enkephalin analogue FK 33-824 on locomotor activity in mice.
Cerebral Infarction
[The effect of FK 506, an immunosuppressant, on cerebral infarction volume in focal cerebral ischemia in rats]
Cholestasis
The use of plasma levels for FK 506 dosing in liver-grafted patients.
Cogan Syndrome
Treatment of Cogan's syndrome with FK 506: a case report.
Coma
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Congenital Abnormalities
[A clinical radiological score for femoral head grafts : Establishment of the Tabea FK score to ensure the quality of human femoral head grafts].
Contracture
Neural activation of opioid mechanisms in guinea pig ileum by excitatory peptides.
Corneal Injuries
Expression and potential role of major inflammatory cytokines in experimental keratomycosis.
MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatment.
The role of fungi in fungal keratitis.
Corneal Opacity
MSCs helped reduce scarring in the cornea after fungal infection when combined with anti-fungal treatment.
Corneal Perforation
Mast Cell Activation Protects Cornea by Promoting Neutrophil Infiltration via Stimulating ICAM-1 and Vascular Dilation in Fungal Keratitis.
Corneal Ulcer
Conjunctival microbiome changes associated with fungal keratitis: metagenomic analysis.
Coronary Artery Disease
Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis.
Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart?
Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration.
Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation.
Cough
Angiotensin-converting enzyme inhibitor and danazol increase sensitivity of cough reflex in female guinea pigs.
Evidence for substance P as an endogenous substance causing cough in guinea pigs.
Role of substance P in cough during bronchoconstriction in awake guinea pigs.
Role of substance P in cough.
The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist.
Crohn Disease
Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum.
Cushing Syndrome
Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.
FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.
Cytomegalovirus Retinitis
Cytomegalovirus retinitis and FK 506.
Dehydration
A novel method for determining rate constants for dehydration of aldehyde hydrates.
Changes in leaf hexokinase activity and metabolite levels in response to drying in the desiccation-tolerant species Sporobolus stapfianus and Xerophyta viscosa.
Fructokinase activity mediates dehydration-induced renal injury.
Identification of proteins regulated by cross-talk between drought and hormone pathways in Arabidopsis wild-type and auxin-insensitive mutants, axr1 and axr2.
Rehydration with Soft Drink-like Beverages Exacerbates Dehydration and Worsens Dehydration-associated Renal Injury.
Demyelinating Diseases
Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats.
Dermatitis
Scratching behavior does not necessarily correlate with epidermal nerve fiber sprouting or inflammatory cell infiltration.
Dermatitis, Allergic Contact
Anti-Inflammatory Effects of Macrophilin-lnteracting Drugs in Animal Models of Irritant and Allergic Contact Dermatitis.
Horizons in pharmacologic intervention in allergic contact dermatitis.
Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?
Dermatitis, Atopic
[FK 506 ointment 0.1 % - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients]
Dermatitis, Contact
Tacrolimus enhances irritation in a 5-day human irritancy in vivo model.
Dermatitis, Irritant
Anti-Inflammatory Effects of Macrophilin-lnteracting Drugs in Animal Models of Irritant and Allergic Contact Dermatitis.
Diabetes Mellitus
Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A.
Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression.
Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.
FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication.
Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study.
Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression.
Diabetes Mellitus, Experimental
Response of hepatic fructokinase to long-term sucrose diets and diabetes in spiny mice, albino mice and rats.
Diabetes Mellitus, Type 1
-to: Pani MA, Van Autreve J, Van der Auwera BJ, Gorus FK, Badenhoop K (2002) Non-transmitted maternal HLA DQ2 or DQ8 alleles and risk of Type 1 diabetes in offspring: the importance of foetal or post partum exposure to diabetogenic molecules. Diabetologia 45:1340-1343.
Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
Use of FK 506 in pancreas transplantation.
Diabetes Mellitus, Type 2
Correction to: Apolipoprotein C3Gene Variants and Risk of Developing Type 2 Diabetes in Saudi Subjects by Alharbi KK, Hussain T, Alharbi FK, Tabassum SN, Mohammed AA, Gambhir D, and Khan IA. Metab Syndr Relat Disord 2015;13;7;298-303 DOI:10.1089/met.2015.0022.
Diabetic Nephropathies
Endogenous Fructose Production and Fructokinase Activation Mediate Renal Injury in Diabetic Nephropathy.
Diphtheria
Psoriasis: mechanisms and entry points for possible therapeutic interventions.
Drug-Related Side Effects and Adverse Reactions
A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression.
New approaches in the use of cyclosporine: with particular reference to the liver.
The immunomodulatory effects of a novel agent, leflunomide, in rat cardiac allotransplantation.
Dry Eye Syndromes
A review of filamentary keratitis.
Dwarfism, Pituitary
Plasma LH, FSH and TSH responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Dyskinesias
Effect of a methionine-enkephalin analog in Huntington's disease.
[Effect of a synthetic analog of enkephalin on the choreic syndrome]
Encephalomyelitis
Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats.
Encephalomyelitis, Autoimmune, Experimental
Effects of FK 506 on acute experimental allergic encephalomyelitis.
Immunoaugmenting effect of FK 506 on experimental allergic encephalomyelitis in Lewis rats.
The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone.
[Effects of novel immunosuppressant FK 506 in acute experimental allergic encephalomyelitis]
Endophthalmitis
Arthrographis kalrae Keratitis Complicated by Endophthalmitis: A Case Report With Literature Review.
Endotoxemia
Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-a production in response to endotoxemia.
Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection?
Enteritis
Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.
[Studies on some characteristics of a strain of mink infectious enteritis virus]
Eosinophilia
Pulmonary infiltrates and eosinophilia in an FK 506 liver transplant recipient.
Epilepsy
Absence of seizure activity following focal cerebral injection of enkephalins in a primate.
Acetone as biomarker for ketosis buildup capability--a study in healthy individuals under combined high fat and starvation diets.
Erythema
Tacrolimus enhances irritation in a 5-day human irritancy in vivo model.
Esophageal Achalasia
Laparoscopic Heller myotomy and Dor fundoplication for the treatment of achalasia. Assessment in relation to morphologic type.
Essential Hypertension
Antihypertensive effect of a new calcium channel blocker, FK 235, in essential hypertension.
Fasciitis, Necrotizing
Necrotizing fasciitis in a renal transplant recipient treated with FK 506: the first reported case.
Fatty Liver
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase.
Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats.
Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver.
Favism
[New acquisitions on the subject of the bio-enzymology of ictero-hemoglobinuric favism. Note I. The enolase, fructokinase and phosphofructokinase activity of the erythrocytes.]
Fetal Growth Retardation
Windows of therapeutic opportunity on fetal growth retardation induced by transient intrauterine ischemia in rats.
fructokinase deficiency
Cyclical dehydration-induced renal injury and Mesoamerican nephropathy: as sweet by any other name?
Enzymes related to fructose utilization in Pseudomonas cepacia.
Inborn errors of fructose metabolism.
Inborn Errors of Fructose Metabolism. What Can We Learn from Them?
Fructose Intolerance
Inborn errors of fructose metabolism.
Inborn Errors of Fructose Metabolism. What Can We Learn from Them?
fructose-bisphosphatase deficiency
Inborn Errors of Fructose Metabolism. What Can We Learn from Them?
fructose-bisphosphate aldolase deficiency
Inborn errors of fructose metabolism.
Gingival Hyperplasia
A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression.
Glioblastoma
[Antitumor efficacy of FK 973 on malignant glioma cells]
Glioma
[Antitumor efficacy of FK 973 on malignant glioma cells]
Glomerulonephritis
Effect of a novel immunosuppressant, FK 506, on autoimmune glomerulonephritis in Brown Norway rats.
Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice.
Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats.
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood.
Glomerulonephritis, Membranous
De novo membranous glomerulopathy in a renal transplant patient treated with FK 506. The first reported case.
Glomerulosclerosis, Focal Segmental
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood.
Glucose Intolerance
Liver AMP/ATP ratio and fructokinase expression are related to gender differences in AMPK activity and glucose intolerance in rats ingesting liquid fructose.
Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients.
Graft vs Host Disease
Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs.
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules.
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats.
FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation.
Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation.
Immunosuppressive power and limitations of FK 506 for prevention and treatment of graft-vs-host disease after small bowel transplantation.
Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506.
[A case of FK 506-induced leukoencephalopathy]
Hallucinations
Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial.
Ketamine and lornoxicam for preventing a fentanyl-induced increase in postoperative morphine requirement.
Heart Arrest
A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.
Heart Failure
Altered interaction of FKBP12.6 with ryanodine receptor as a cause of abnormal Ca(2+) release in heart failure.
Diabetic Cardiomyopathy: The Case for a Role of Fructose in Disease Etiology.
Sarcoplasmic reticulum calcium release function and FK binding proteins in heart failure: another piece of a complex jigsaw.
Hemolytic-Uremic Syndrome
FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient.
Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.
Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome.
Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome.
Hepatitis
FK 506 modulates D-galactosamine-induced hepatitis in rats.
Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine.
[ACTIVITY OF LIVER FRUCTOKINASE IN VIRAL HEPATITIS.]
[BEHAVIOR OF FRUCTOSE AND INORGANIC PHOSPHORUS FOLLOWING ORAL SACCHAROSE LOAD AS AN INDEX OF FRUCTOSE METABOLISM. FRUCTOKINASE ACTIVITY OF THE LIVER IN VIRAL HEPATITIS.]
Hepatitis C
A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease.
Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients.
Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease.
Hirsutism
A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression.
Huntington Disease
Effect of a methionine-enkephalin analog in Huntington's disease.
Hypercholesterolemia
Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506.
Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Hyperglycemia
Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation.
Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients.
Hyperkalemia
Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
Hyperprolactinemia
Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Plasma LH, FSH and TSH responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Hypersensitivity
Comparison of topical dexamethasone and topical FK506 treatment for the experimental allergic conjunctivitis model in BALB/c mice.
Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats.
Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?
Hypertension
A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression.
A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.
Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
Effect of FK 506 on the expression of endothelin receptor mRNA in the vasculature.
FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results.
Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Mechanisms of FK 506-induced hypertension in the rat.
Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation.
Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients.
Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo.
Tailored dialysis start may allow persistence of residual renal function after graft failure: a case report.
The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist.
Hypertension, Portal
FK 409 ameliorates small-for-size liver graft injury by attenuation of portal hypertension and down-regulation of Egr-1 pathway.
Hypokinesia
Enkephalin, morphine, and naloxone in tardive dyskinesia.
Hypotension
Cardiorespiratory effects of D-Ala-2-Me-Phe-4-Met-(0)-ol enkephalin in the third ventricle, and in anterior hypothalamic and paraventricular areas of the rat brain.
Cardiorespiratory responses to D-Ala-2-Me-Phe-4-Met-(O)-ol-enkephalin after administration into the fourth cerebral ventricle of the rat: interaction with cholinergic mechanisms.
Infections
A novel 3D culture model of fungal keratitis to explore host-pathogen interactions within the stromal environment.
A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation.
Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study.
Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.
Antimicrobial peptides in human corneal tissue of patients with fungal keratitis.
CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression.
Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics.
Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation--incidence, location, and severity in cyclosporine- and FK506-treated patients.
Early infections in kidney transplant recipients under FK 506.
Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report.
Evaluation of Liposomal and Conventional Amphotericin B in Experimental Fungal Keratitis Rabbit Model.
FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results.
Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Gene profiling in murine corneas challenged with Aspergillus fumigatus.
High incidence of severe infections in heart transplant recipients receiving tacrolimus.
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.
Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation.
Infections in adult liver transplant patients under FK 506 immunosuppression.
Infections with FK 506 immunosuppression: preliminary results with primary therapy.
Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.
Medication review: FK 506.
Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
Phenotype of immunosuppression reduction after kidney transplantation.
Postoperative selective bowel decontamination prevents gram-negative bacterial translocation in small-bowel graft recipients.
Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
Recipient FK506 pretreatment regimens in rat small bowel transplantation: allograft survival, function, and systemic infection.
Tacrolimus vs Neoral in renal and renal/pancreas transplantation.
Therapeutic drug monitoring for immunosuppressants.
Insulin Resistance
Cacao extract enriched in polyphenols prevents endocrine-metabolic disturbances in a rat model of prediabetes triggered by a sucrose rich diet.
Chronic Glucocorticoid-Rich Milieu and Liver Dysfunction.
Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique.
Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection?
Intestinal Failure
Technical aspects of intestinal transplantation.
Keratitis
Altered Patterns of Fungal Keratitis at a London Ophthalmic Referral Hospital: An Eight-Year Retrospective Observational Study.
Antimicrobial peptides in human corneal tissue of patients with fungal keratitis.
Baicalein Protects Against Aspergillus fumigatus Keratitis by Reducing Fungal Load and Inhibiting TSLP-Induced Inflammatory Response.
Bilateral Trichosporon asahii keratitis after ptosis correction: A case report.
Comparison of fungal and bacterial keratitis between tropical and subtropical Taiwan: a prospective cohort study.
Corneal Higher-Order Aberrations in Infectious Keratitis.
Diagnostic Evaluation of Co-Occurrence of Acanthamoeba and Fungi in Keratitis: A Preliminary Report.
Early expression of PTX3 in Aspergillus fumigatus infected rat cornea.
Gene profiling in murine corneas challenged with Aspergillus fumigatus.
Isorhamnetin Ameliorates Aspergillus fumigatus Keratitis by Reducing Fungal Load, Inhibiting Pattern-Recognition Receptors and Inflammatory Cytokines.
Lipoxin A4 activates ALX/FPR2 to attenuate inflammation in Aspergillus fumigatus keratitis.
Multi-locus DNA sequence analysis, antifungal agent susceptibility, and fungal keratitis outcome in horses from Southeastern United States.
Quercetin amelioratesAspergillus fumigatuskeratitis by inhibiting fungal growth, toll-like receptors and inflammatory cytokines.
The role of Mincle in innate immune to fungal keratitis.
Topical Corticosteroids for Infectious Keratitis Before Culture-Proven Diagnosis.
Treatment of Refractory Filamentary Keratitis With Autologous Serum Tears.
[Spectrum of infection of fungal keratitis: analysis of 654 cases]
Kidney Diseases
The sweetest thing: blocking fructose metabolism to prevent acute kidney injury?
Leukemia
[A case of FK 506-induced leukoencephalopathy]
Leukemia, Myelomonocytic, Acute
[A case of FK 506-induced leukoencephalopathy]
Leukoencephalopathies
FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report.
[A case of FK 506-induced leukoencephalopathy]
Liver Diseases
Comparison of different assays for the quantitation of FK 506 levels in blood or plasma.
Conversion from cyclosporin to FK 506 after liver transplantation.
Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.
Liver Failure, Acute
FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
Lupus Nephritis
Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
Lymphadenopathy
FK 506 associated disorders in liver transplantation.
Lymphocytosis
Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.
Lymphoma
Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t(2;3)(p11;q27) from a liver transplant patient.
Use of FK 506 in pancreas transplantation.
Lymphoma, B-Cell
Use of FK 506 in pancreas transplantation.
Lymphomatoid Papulosis
Lymphomatoid papulosis and FK 506.
Lymphoproliferative Disorders
FK 506 associated disorders in liver transplantation.
Lymphoproliferative disorder in a liver transplant patient on FK 506.
Lymphoproliferative disorders after FK 506.
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.
Malabsorption Syndromes
[Immunosuppression: a case of mucoviscidosis]
Medulloblastoma
[Antitumor efficacy of FK 973 on malignant glioma cells]
Metabolic Diseases
Endogenous fructose production: what do we know and how relevant is it?
Metabolic Syndrome
Deletion of Fructokinase in the Liver or in the Intestine Reveals Differential Effects on Sugar-Induced Metabolic Dysfunction.
Fructokinase, Fructans, Intestinal Permeability, and Metabolic Syndrome: An Equine Connection?
Gout and Metabolic Syndrome: a Tangled Web.
Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice.
Opposite fates of fructose in the development of metabolic syndrome.
Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake.
Sugar causes obesity and metabolic syndrome in mice independently of sweet taste.
Multiple Sclerosis
Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy.
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.
[Current therapy of multiple sclerosis: value of cyclosporin A and FK 506]
Multiple Sclerosis, Chronic Progressive
Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.
Myasthenia Gravis
Benefits of FK 506 for refractory eye symptoms in a young child with ocular myasthenia gravis.
Mycoses
Persistence of Innate Immune Pathways in Late Stage Human Bacterial and Fungal Keratitis: Results from a Comparative Transcriptome Analysis.
Reducing mortality associated with immediate treatment complications of adult leukemias.
Therapeutic effects of an anti-IL-6 antibody in fungal keratitis: Macrophage inhibition and T cell subset regulation.
Myocarditis
Impact of FK 506 on myocarditis in the enteroviral murine model.
Pharmacotherapy of dilated cardiomyopathy: current status and future directions.
Myotoxicity
Myotoxicity of amine metabolites from Brown FK.
Neoplasm Metastasis
Alteration of opioid peptide circadian rhythm in cancer patients.
Neoplasms
A brief history of the pathology of the gonads.
A comparative study on immunosuppressive effects of cyclosporin A and FK 506 on peripheral blood lymphocytes in dogs.
A fusion fragment from Flt-1 and KDR, acted as VEGF decoy receptor and exhibited anti-tumor function
A fusion fragment from Flt-1 and KDR, acted as VEGF decoy receptor and exhibited anti-tumor function.
Alteration of opioid peptide circadian rhythm in cancer patients.
Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CX3CL1.
Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders.
Evidence for altered opioid activity in patients with cancer.
FK 506 ameliorates normothermic liver ischemia in rats by suppressing production of tumor necrosis factor.
FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion.
Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Fructokinase, triokinase, and aldolases in liver tumors of the rat.
Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
Immunosuppressive drugs and their effect on experimental tumor growth.
Non-lymphoid cancer after liver transplantation.
Psoriasis: mechanisms and entry points for possible therapeutic interventions.
Suppressive effects of 1,4-dihydroxy-2-naphthoic acid administration on bone resorption.
The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62.
Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine.
[Experimental gene therapy mediated by fractalkine (FK) for murine liver cancer]
Nephrosis, Lipoid
FK 506 for vascular permeability factor production in minimal change nephrotic syndrome.
Nephrotic Syndrome
FK 506 for vascular permeability factor production in minimal change nephrotic syndrome.
FK 506 in the management of nephrotic syndrome after renal transplantation.
FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome.
Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.
Nervous System Diseases
FK 506 versus cyclosporin in the prevention of renal allograft rejection--European pilot study: six-week results.
Neuralgia
Calcineurin-inhibitor-induced pain syndrome after bone marrow transplantation.
Neuroblastoma
[Antitumor efficacy of FK 973 on malignant glioma cells]
Neurodegenerative Diseases
Distribution of immunophilin FKBP-12 protein and mRNA within the mammalian cochlea and cochlear nucleus.
Neurofibroma
Mast cells migrate, but do not degranulate, in response to fractalkine, a membrane-bound chemokine expressed constitutively in diverse cells of the skin.
Neurologic Manifestations
Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy.
Neutropenia
FK 506 associated disorders in liver transplantation.
[Use of Sirolimus in five pediatric patients undergoing solid organ transplantation]
Non-alcoholic Fatty Liver Disease
Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
Obesity
High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase.
Ocular Hypertension
[Comment on Velten IM, Bergua A, Horm FK, Junemann A, Korth M. "Central corneal thickness in normal probands, patients with ocular hypertension, normal pressure and open-angle glaucomas--a clinical study"]
Oliguria
Corticosteroids and concomitant medication in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Opportunistic Infections
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Paralysis
[Comment on Beller FK. Incidence and causes of upper arm plexus paralysis in newborn infants. An overview and basic principles of legal considerations]
Paresis
Transient diffusion-weighted imaging changes in a patient with reversible leukoencephalopathy syndrome.
Peripheral Nervous System Diseases
Toxic neuropathies.
Pituitary ACTH Hypersecretion
Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.
FK 33-824, a met-enkephalin analog, blocks corticotropin-releasing hormone-induced adrenocorticotropin secretion in normal subjects but not in patients with Cushing's disease.
Pituitary Diseases
Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Pituitary Neoplasms
Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.
Plasma LH, FSH and TSH responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Plasma pituitary hormone responses to the synthetic enkephalin analog (FK 33-824) in normal subjects and patients with pituitary diseases.
Pleurisy
Characterization of the receptor and the mechanisms underlying the inflammatory response induced by des-Arg9-BK in mouse pleurisy.
Pneumonia, Bacterial
A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.
Pneumoperitoneum
Addition of Low-Dose Ketamine to Propofol-Fentanyl Sedation for Gynecologic Diagnostic Laparoscopy: Randomized Controlled Trial.
Polyneuropathies
[Acute peripheral demyelinating polyneuropathy and acute renal failure after administration of FK506]
Porcine Reproductive and Respiratory Syndrome
Persistence of Innate Immune Pathways in Late Stage Human Bacterial and Fungal Keratitis: Results from a Comparative Transcriptome Analysis.
Prolactinoma
Persistence of a defective tuberoinfundibular dopaminergic function in rats after long-term removal of oestrogen treatment. An in vivo study.
Proteinuria
Effect of a novel immunosuppressant, FK 506, on autoimmune glomerulonephritis in Brown Norway rats.
Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats.
Is sirolimus responsible for proteinuria?
Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.
Psoriasis
FK 506: a new therapeutic agent for severe recalcitrant psoriasis.
ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy.
Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases.
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group.
The effect of cyclosporin A and FK 506 on the cAMP content in psoriatic keratinocytes.
Pulmonary Disease, Chronic Obstructive
[Modern tendencies in co-morbid conditions].
Pyelonephritis
Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506.
Pyoderma Gangrenosum
Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum.
Renal Insufficiency
Comparison of short and long-term renal function in liver transplant patients receiving cyclosporin or FK 506.
Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients.
Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.
Reperfusion Injury
A spontaneous nitric oxide donor ameliorates small bowel ischemia-reperfusion injury in dogs.
Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver.
Beneficial effects of FK409, a novel nitric oxide donor, on reperfusion injury of rat liver.
FK 506 ameliorates normothermic liver ischemia in rats by suppressing production of tumor necrosis factor.
Modulation of endothelin and nitric oxide: a rational approach to improve canine hepatic microcirculation.
NO donor ameliorates ischemia-reperfusion injury of the rat liver with iNOS attenuation.
Prior induction of heat shock proteins by a nitric oxide donor attenuates cardiac ischemia/reperfusion injury in the rat.
The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs.
The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model.
The effects of a cyclooxygenase-2 inhibitor, FK3311, on total hepatic ischemia-reperfusion injury of the rat.
The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury.
Respiratory Insufficiency
Addition of Low-Dose Ketamine to Propofol-Fentanyl Sedation for Gynecologic Diagnostic Laparoscopy: Randomized Controlled Trial.
Cardiorespiratory responses to D-Ala-2-Me-Phe-4-Met-(O)-ol-enkephalin after administration into the fourth cerebral ventricle of the rat: interaction with cholinergic mechanisms.
D-Ala-2-Me-Phe-4-Met-(O)-ol-enkephalin in the nucleus tractus solitarius of the rat produces cardiorespiratory depression.
Effects of the enkephalin analogue FK33-824 on rectal temperature and respiratory rate in male mice.
Perfusion of the fourth cerebral ventricle with the synthetic opioid peptide, FK 33-824, induces dose-related bradycardia and naloxone-reversible respiratory depression in the awake dog.
Retinitis
CMV retinitis and the use of FK 506.
Cytomegalovirus retinitis and FK 506.
Seizures
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient.
Sepsis
Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection.
Intestinal transplantation at the University of Pittsburgh.
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.
Skin Diseases
Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?
Sleep Initiation and Maintenance Disorders
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Spinal Cord Injuries
FK 506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat.
Spinal Cord Ischemia
Immunophilin ligands FK506 and cyclosporine A improve neurologic and histopathologic outcome after transient spinal cord ischemia in rabbits.
Staphylococcal Infections
Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics.
Starvation
In situ activities of hexokinase and fructokinase in relation to phosphorylation status of root meristem cells of Vicia faba during reactivation from sugar starvation
In situ activities of hexokinase and fructokinase in relation to phosphorylation status of root meristem cells of Vicia faba during reactivation from sugar starvation.
Status Epilepticus
Transient diffusion-weighted imaging changes in a patient with reversible leukoencephalopathy syndrome.
Stroke
FK 506 protects brain tissue in animal models of stroke.
Tachycardia
Coronary and systemic hemodynamic effects of the putative nitric oxide donor, FK 409, in comparison with nitroglycerin in conscious and anesthetized dogs.
Tardive Dyskinesia
Enkephalin, morphine, and naloxone in tardive dyskinesia.
Testicular Neoplasms
A brief history of the pathology of the gonads.
Tetanus
Regulation of antigen-induced human T-lymphocyte responses by calcineurin antagonists.
Thrombocytopenia
FK 506 associated disorders in liver transplantation.
Thrombosis
Histocompatibility and liver transplantation.
Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras.
Thyroid Diseases
Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat.
Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.
Thyroiditis, Autoimmune
Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.
Tremor
Neurological complications in the European multicentre study of FK 506 and cyclosporin in primary liver transplantation.
Neurological examinations after liver transplantation concerning patients under corticosteroid immunosuppression and either FK 506 or cyclosporin.
Severe neurological complications following orthotopic liver transplantation in patients receiving FK 506 and prednisone.
Uveitis
A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis.
Vasculitis
Original Article: Cyclosporine a and FK 506 Affect Platelet Functions in Vitro.
Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443.
Vasculitis, Central Nervous System
Cerebral vasculitis during FK 506 treatment in a liver transplant patient.
Virus Diseases
Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients.
Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease.
[Optimization of renal transplantation]
Vision Disorders
The role of fungi in fungal keratitis.
Whooping Cough
Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro.